Stephane Boissel CEO, TxCell Luca Alberici Chief Business Officer, MolMed Evren Alici CEO; Director, Cell & Gene Therapy Centre, Vycellix; Karolinska Institutet Diego Ardigo Head R&D Rare Diseases Unit Head, Chiesi Farmaceutici SpA Usman ”Oz” Azam President CEO, Tmunity Therapeutics Stefano Baila Director of Operations & Business Development, Amenocyte Jacqueline Barry Chief Clinical Officer, Cell and Gene Therapy Catapult Sharon Benzeno Senior Vice President, Research and Business Development, Adaptive Biotechnologies Corp. Maina Bhaman Partner, Sofinnova Partners Steven Binninger Cell Therapy Business Lead, ELAMA, Fresenius Kabi Louise Bisset Senior Biologicals Quality Assessor, Medicines and Healthcare Products Regulatory Agency Jasper Bos Vice President and Head of Healthcare, Merck Ventures Christopher Bravery Director, Advanced Biologicals Ltd Massimilano Cesarini Global Sales Manager, Comecer Dominic Clarke Global Head of Cell Therapy, HemaCare Danielle M.J. Curfs CEO and Co-Founder, Medace Sybil Danby Director Business Development, Paragon Bioservices Doug Danison Vice President and Head of Access, Value, and Evidence Strategy (AVES), bluebird bio Anthony Davies President, Dark Horse Consulting Pam Dhadda Regulatory Affairs Consultant, Cell & Gene Therapy, ERA Consulting Mark Dudley SVP, Product Development, Adaptimmune Lindy Durrant CSO; Academic Clinical Oncology, Scancell; University of Nottingham Andreas Eberle Vice President & Head of Manufacturing, Co.Don AG Simon Ellison Cell & Gene Therapy Service Director, World Courier Victoria English Editor, MedNous Farzin Farzaneh Head of Molecular Medicine, Kings College London Nicole Faust CEO & CSO, CEVEC Pharmaceuticals Thomas Fellner Head of Cell & Gene Therapy, Lonza Pharma & Biotech Chris Fisher Director of Technical Operations, Autolus Ltd Kerry Fisher Research Lecturer, Oxford University Mark Flower Vice President, Business Development and Strategic Partnerships , Be The Match BioTherapies Miguel Forte Chief Executive Officer, Zelluna Immunotherapy Michela Gabaldo Head, Alliance Management & Regulatory Affairs, San Raffaele-Telethon Institute for Gene Therapy Mehdi Gasmi Chief Science & Technology Officer, Adverum Biotech Markus Gershater Chief Scientific Officer & Co-Founder, Synthace 1 2 3
Phacilitate have grown side by side with you –through the bad & the good - since 2005 and we care about what happens next, just as much as you do. Evolution!
Our sponsors make this event special and want to say thanks for their continued support. Sponsors confirmed
View our expert speaker line up we have confirmed so far. More to follow soon so keep coming back to check who is coming to speak this year! Speaker list
Bringing Cell and Gene Therapy Europe to London this year and merging with Immuno-Oncology Frontiers to create Phacilitate Leaders Europe. Cell & Gene Therapy Europe
Immuno-Oncology Frontiers is merging with Cell and Gene Therapy Europe this year as we evolve and grow with the industry. Immuno-Oncology Frontiers
Advanced therapies are reaching a maturation point but without sustainable, global investment we’ll stop seeing revolutions in the future of healthcare. Investment for Advanced Therapies
